The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
Abstract
Deprenyl (selegiline) delays the need for levodopa therapy in patients with early Parkinson's disease, but the long‐term benefits of this treatment remain unclear. During 1987 to 1988, 800 patients with early Parkinson's disease were randomized in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism trial to receive deprenyl, tocopherol, combined treatments, or a placebo and were then placed on active deprenyl (10mg/day). A second, independent randomization was carried out in early 1993 for 368 subjects who by that time had required levodopa and who had consented to continuing the deprenyl treatment (D subjects) or changing to a matching placebo (P subjects) under double‐blind conditions. The first development of wearing off, dyskinesias, or on–off motor fluctuations was the prespecified primary outcome measure. During the average 2‐year follow‐up, there were no differences between the treatment groups with respect to the primary outcome measure (hazard ratio, 0.87; 95% confidence interval, 0.63, 1.19;p= 0.38), withdrawal from the study, death, or adverse events. Although 34% of D subjects developed dyskinesias and only 19% of P subjects did (p= 0.006), only 16% of D subjects developed freezing of gait but 29% of P subjects did (p= 0.0003). Decline in motor performance was less in D subjects than P subjects. Levodopa‐treated Parkinson's disease patients who had been treated with deprenyl for up to 7 years, compared with patients who were changed to a placebo after about 5 years, experienced slower motor decline and were more likely to develop dyskinesias but less likely to develop freezing of gait.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
Self-citationPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Self-citationPramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Freezing of gait in PD: Prospective assessment in the DATATOP cohort
Giladi, N., McDermott, M. P., Fahn, S., Przedborski, S., Jankovic, J., Stern, M., Tanner, C., & The Parkinson Study Group (2001) · Neurology · doi:10.1212/wnl.56.12.1712 · Cited by 545
Self-citationParkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
DATATOP: A decade of neuroprotective inquiry
Shoulson, I., & Parkinson Study Group (1998) · Annals of Neurology · doi:10.1002/ana.410440724 · Cited by 201
Self-citationParkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390106 · Cited by 170
Cited by
Bloem, B. R., Hausdorff, J. M., Visser, J. E., & Giladi, N. (2004) · Movement Disorders · doi:10.1002/mds.20115 · Cited by 1,297
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Description of Parkinson's Disease as a Clinical Syndrome
FAHN, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 977
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationMissing pieces in the Parkinson's disease puzzle
Obeso, J. A., Rodriguez-Oroz, M. C., Goetz, C. G., Marin, C., Kordower, J. H., Rodriguez, M., Hirsch, E. C., Farrer, M., Schapira, A. H. V., & Halliday, G. (2010) · Nature Medicine · doi:10.1038/nm.2165 · Cited by 734
Schaafsma, J. D., Balash, Y., Gurevich, T., Bartels, A. L., Hausdorff, J. M., & Giladi, N. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00611.x · Cited by 725
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Validation of the freezing of gait questionnaire in patients with Parkinson’s disease
Giladi, N., Tal, J., Azulay, T., Rascol, O., Brooks, D. J., Melamed, E., Oertel, W., Poewe, W. H., Stocchi, F., & Tolosa, E. (2009) · Movement Disorders · doi:10.1002/mds.21745 · Cited by 431
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Finberg, J. P. M., & Rabey, J. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00340 · Cited by 432
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Self-citationLeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group (2008) · Annals of Neurology · doi:10.1002/ana.21315 · Cited by 356
Self-citationFerreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Current approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Fahn, S. (2008) · Movement Disorders · doi:10.1002/mds.22028 · Cited by 339
Self-citationDiagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Falls in outpatients with Parkinson's disease: Frequency, impact and identifying factors
Balash, Y., Peretz, C., Leibovich, G., Herman, T., Hausdorff, J. M., & Giladi, N. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0855-3 · Cited by 275
Selegiline slows the progression of the symptoms of Parkinson disease
Pålhagen, S., Heinonen, E., Hägglund, J., Kaugesaar, T., Mäki-Ikola, O., Palm, R., & the Swedish Parkinson Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000204007.46190.54 · Cited by 271
Self-citationNeurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Self-citationAntioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
How do you treat motor complications in Parkinson's disease: medicine, surgery, or both?
Fahn, S. (2009) · Annals of Neurology · doi:10.1002/ana.21453 · Cited by 66
Self-citationClinicopathological characteristics of freezing of gait in autopsy‐confirmed Parkinson's disease
Virmani, T., Moskowitz, C. B., Vonsattel, J., & Fahn, S. (2015) · Movement Disorders · doi:10.1002/mds.26346 · Cited by 56
Self-citation
Metadata
- Authors
- Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., Rudolph, A., & the Parkinson Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-04-23
- Volume
- 51
- Issue
- 5
- Pages
- 604-612
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2103120760
- Cited by
- 258
- References
- 18
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.